Par Drugs and Chemicals Limited (IN:PAR)
:PAR
Want to see IN:PAR full AI Analyst Report?
Top Page
Par Drugs and Chemicals Limited
(PAR)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹106.00
▲(5.02% Upside)
Action:Reiterated
Date:06/16/26
The score is supported primarily by strong financial quality (notably zero debt and steady balance-sheet growth) and a low P/E valuation. This is tempered by mixed technical signals (negative MACD and price still below the 200-day average) and some variability in growth, margins, and cash conversion.
Positive Factors
Balance sheet strength
Zero reported debt and steady equity/assets growth materially lower financial risk and preserve strategic optionality. Over a multi‑month horizon this supports continued R&D or targeted M&A, cushions cyclical pharma demand, and reduces refinancing vulnerability.
Negative Factors
Inconsistent revenue growth
Uneven top‑line trends complicate medium‑term planning and indicate demand or product‑mix instability. That variability makes it harder to scale fixed costs, forecast R&D returns, and sustain investment cadence needed to strengthen market position over 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported debt and steady equity/assets growth materially lower financial risk and preserve strategic optionality. Over a multi‑month horizon this supports continued R&D or targeted M&A, cushions cyclical pharma demand, and reduces refinancing vulnerability.
Read all positive factors
Par Drugs and Chemicals Limited (PAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.15B
Dividend YieldN/A
Average Volume (3M)31.06K
Price to Earnings (P/E)9.0
Beta (1Y)0.96
Revenue Growth2.66%
EPS Growth-1.90%
CountryIN
Employees122
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)7.87
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Par Drugs and Chemicals Limited Business Overview & Revenue Model
Company Description
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds,...
How the Company Makes Money
null...
Par Drugs and Chemicals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
77
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 984.16M | 1.04B | 1.01B | 956.40M | 950.95M | 746.15M |
| Gross Profit | 577.71M | 504.71M | 628.43M | 609.88M | 286.90M | 243.36M |
| EBITDA | 160.65M | 171.31M | 195.01M | 229.53M | 184.46M | 163.61M |
| Net Income | 96.87M | 131.09M | 133.58M | 145.01M | 113.34M | 92.13M |
Balance Sheet | ||||||
| Total Assets | 1.28B | 1.29B | 1.19B | 1.02B | 888.68M | 786.90M |
| Cash, Cash Equivalents and Short-Term Investments | 338.56M | 418.43M | 275.77M | 366.54M | 222.43M | 162.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 210.91M | 172.28M | 204.15M | 159.79M | 176.30M | 188.13M |
| Stockholders Equity | 1.06B | 1.12B | 989.75M | 856.32M | 712.38M | 598.77M |
Cash Flow | ||||||
| Free Cash Flow | 73.74M | 144.71M | 149.34M | 141.69M | 57.44M | 44.13M |
| Operating Cash Flow | 80.95M | 164.32M | 161.60M | 202.49M | 133.77M | 76.15M |
| Investing Cash Flow | -18.16M | -21.66M | -252.37M | -58.38M | -73.38M | -30.18M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -24.00K | -95.54M |
Par Drugs and Chemicals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹1.15B | 8.97 | ― | ― | 2.66% | -1.90% | |
65 Neutral | ₹1.98B | 8.08 | ― | ― | 3.85% | ― | |
61 Neutral | ₹1.48B | 26.80 | ― | ― | -5.91% | -26.95% | |
53 Neutral | ₹1.41B | 22.57 | ― | 1.62% | 2.83% | -26.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹579.84M | 20.59 | ― | ― | -14.99% | 399.30% | |
39 Underperform | ₹522.36M | -1.47 | ― | ― | -35.33% | -65.64% |
* Healthcare Sector Average
IN:PAR
Par Drugs and Chemicals Limited
95.08
-1.59
-1.64%
IN:ALPA
Alpa Laboratories Limited
70.61
-29.15
-29.22%
IN:BALPHARMA
Bal Pharma Limited
88.85
-8.97
-9.17%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
35.10
-15.41
-30.51%
IN:BROOKS
Brooks Laboratories Limited
67.22
-55.88
-45.39%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.30
1.40
28.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.